Skip to content

Learn about REMICADE efficacy for the treatment of chronic severe plaque psoriasis

Psoriasis is a chronic inflammatory disease of the skin affecting at least 5.8 million people in the United States and 125 million people worldwide (National Psoriasis Foundation 2007; Gelfand et al 2005). Data show patients with severe psoriasis affecting the nails experienced significant improvements with Remicade therapy. In September 2006, REMICADE was approved for the treatment of adult patients with chronic severe plaque psoriasis. Tell your doctor if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as feeling unwell, poor appetite, tiredness, fever, skin rash and/or joint pain. Public Release: 2-Feb-2007 Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis. Tell your doctor if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as feeling unwell, poor appetite, tiredness, fever, skin rash and/or joint pain.

Learn about REMICADE efficacy for the treatment of chronic severe plaque psoriasis 2The safety and efficacy of infliximab monotherapy will be evaluated. Pregnant, nursing, or planned pregnancy within 6 months after last scheduled treatment. To address the unmet medical need for effective chronic therapies, TNFalpha blockers have recently been used to treat patients with moderate to severe plaque psoriasis. Have plaque psoriasis despite at least 4 months of treatment with etanercept per current product labeling. Remicade is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV reactivation.

Efficacy and safety of infliximab therapy in plaque psoriasis patients previously treated with etanercept: Analysis of PSUNRISE (Abstract P3341). Treatment of adult patients with chronic severe plaque PsO who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. You should let your doctor know if you have or ever had any of the following:. Severe flares are usually treated with steroid medications to obtain remission, but steroids have many undesirable side effects, so some gastroenterologists are now advocating the use of infliximab as the first drug to try to get patients into remission. It is also used to treat severe or disabling plaque psoriasis (raised, silvery flaking of the skin). Common side effects of Remicade include headache, stomach pain, nausea, stuffy nose, sinus pain, skin rash, or flushing (warmth, redness, or tingly feeling).

A Study To Evaluate Remicade (infliximab) In Moderate-to-severe Chronic Plaque Psoriasis In The Middle Eastern Population (study P04528)

Psoriasis is a common chronic skin disease characterized by cutaneous inflammation and epidermal hyperproliferation. In the 54-week, open-label study of patients with moderate-to-severe plaque psoriasis, the results found both treatment groups had significant improvement in PASI scores from baseline to week 54 (68 and 59, respectively). Phase 3 data show treatment with REMICADE (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. We now have data showing that the majority of patients receiving scheduled REMICADE maintenance therapy achieved long-term clinical response in psoriasis, a lifelong, chronic inflammatory disease said Alan Menter, MD, chairman, Division of Dermatology, Baylor University Medical Center, and lead study investigator. The aim of this systematic review is to evaluate efficacy and safety of off-label dosing regimens (dose escalation, dose reduction, and interrupted treatment) with etanercept, adalimumab, infliximab, ustekinumab, and alefacept for psoriasis treatment. Learn More Submit Now. Psoriasis is a chronic, inflammatory skin disease associated with comorbidities, psychosocial impairment, and markedly reduced quality of life 1, 2. The safety and efficacy of etanercept, adalimumab, infliximab, ustekinumab, and alefacept for the long-term treatment of adults with moderate-to-severe plaque psoriasis have been previously established in large randomized, double blind, placebo-controlled clinical trials 15 22. REMICADE is an advanced biologic treatment for chronic severe plaque psoriasis, requiring as few as six treatments a year after an initial three treatments. Tell your doctor if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as feeling unwell, poor appetite, tiredness, fever, skin rash and/or joint pain. FDA approves Inflectra, a biosimilar to Remicade. Biosimilars can provide access to important treatment options for patients who need them, said Janet Woodcock, M. The biosimilar also must show it has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. Patients should let their doctors know if they have or ever had any of the following:.

Stelaratm And Data In Treatment Of Plaque Psoriasis To Be Presented At American Academy Of Dermatology (aad) Meeting (nyse:jnj)

Patients were also asked to compare the efficacy of etanercept and adalimumab on PsA subjectively at Week 24. To decline or learn more, visit our Cookies page. Before the first biologic for psoriasis was FDA-approved, treatment options consisted of topical agents, phototherapy, and conventional systemic agents. Adalimumab The REVEAL The Randomized Controlled Evaluation of Adalimumab Every Other Week in Moderate to Severe Psoriasis Trial study was a randomized, double-blind, placebo-controlled, phase 3 trial that evaluated the safety and efficacy of adalimumab in 1212 patients with moderate-to-severe chronic plaque psoriasis over the course of 52 weeks.